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The rationale
In this debate, the author takes the position that LDL cho-
lesterol is a major causative factor in the huge prevalence
and incidence of arteriosclerotic disease that has plagued
the Western World and which is now growing rapidly in
developing countries [1]. In examining population data, the
risk of clinical vascular disease is a continuous function of
rising plasma cholesterol, which is attributable to a rise in
LDL cholesterol [2]. Those cultures estimated to have life-
long LDL cholesterol values at or below 100 mg/dl have
previously experienced myocardial infarction and coronary
death rates that are 70 to 90% below those in Eastern
Europe where LDL has been 50 to 70% higher [3]. As eco-
nomic changes have brought about dietary changes,
plasma cholesterol levels have risen, as have other major
risk factors such as obesity and diabetes. Even in societies
with low total cholesterol levels, preliminary evidence indi-
cates that declining risk extends to values below 160 mg/dl
(4.2 mmol/l), which is equivalent to an LDL level of approxi-
mately 100 mg/dl (2.6 mmol/l) [4]. Lowering plasma cho-
lesterol by a variety of means — including diet, surgical
bypass of the distal ileum, bile acid sequestrants, fibric acid
derivatives and most recently statins — has led to a reduc-
tion in events both in patients with known clinical vascular
disease as well in those without [5–13]. It is highly proba-
ble that reducing the population distribution curve of LDL
cholesterol values to a mean of around 100 mg/dl (total
cholesterol of approximately 150–160 mg/dl) would cause
a major change in the incidence of this problem. Further-
more, reductions well below 100 mg/dl, where feasible and
cost effective, are predicted to give an additional margin of
protection that could save millions of lives.
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Arteriosclerotic vascular disease manifests as heart disease, stroke, aortic aneurysms, and peripheral
vascular disease, and is a growing problem world-wide. The preventive efforts made so far have
demonstrated that lowering LDL-C is one action that individuals and populations can do with
significant success in delaying the onset of clinical events. Epidemiological studies and small clinical
trials suggest that more aggressive and sustained lowering to LDL-C below 100 mg/dl could result in
50 to 70% reductions in vascular death. The full benefit of reducing LDL-C is only now being tested in
adequate clinical trials.
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Expert opinion
The National Cholesterol Education Program (NCEP) in
the US and the Joint European Commission have taken
the position that health care providers should set the most
aggressive treatment goals in those at highest risk
[14,15]. The NCEP has chosen the LDL-C target of less
than 100 mg/dl for all patients with clinically evident arte-
riosclerotic vascular disease. Furthermore, this organiza-
tion is considering using other indicators of impending
events, such as diabetes mellitus, reduced ankle/arm
blood pressure ratios, and integrated risk analysis (‘global
risk’), to define additional populations that should be
included in this LDL-C goal. The European recommenda-
tions suggest setting an LDL-C goal of 115 mg/dl
(3.0 mmol/l), or less, in those patients with a global risk
analysis that predicts a 20% probability of having a
myocardial infarction (MI) or coronary artery death (CAD)
in the next 10 years [15]. Accordingly, we will attempt to
develop the argument for reducing the LDL cholesterol to
values below 100 mg/dl (2.6 mmol/l) by sequentially
focusing on defined populations ranked by increasing risk
of suffering a major cardiovascular event.
Clinical trial evidence
Those at highest risk are patients who have suffered a
recent major spontaneous event such as a myocardial
infarction or hospitalization for unstable angina. Recurrent
hospitalization for CAD or coronary death occurs in 12 to
20% of this group within 1 year [16]. The recently reported
Myocardial Ischemia Reduction with Aggressive Choles-
terol Lowering trial (MIRACL) [17, 18] selected 3080
patients in hospital for non-Q wave MI or unstable angina
and randomly assigned them to receive atorvastatin
(80 mg/d) or placebo for four months. Initially the LDL-C
was only 124 mg/dl. By the end of the study, it had risen to
135 mg/dl in the control group but had been reduced to
72 mg/dl in those on the statin. Those treated with atorvas-
tatin had experienced 16% fewer endpoints defined as
‘primary’ (14.8% versus 17.4%). These included total death,
nonfatal acute MI, cardiac arrest with resuscitation, and
urgent hospitalization for angina (with objective evidence of
ischemia). The hospitalizations for angina, when considered
alone, were reduced by 26% (6.2% versus 8.4%). In addi-
tion, a reduction in non-fatal stroke of 50% was observed.
All of these differences were statistically significant.
A second high-risk group consists of those symptomatic
patients who are evaluated by coronary angiography and
who are found to be suitable for treatment with percuta-
neous transluminal coronary angioplasty. The Atorvastatin
Versus Revascularization Treatments (AVERT) study [19]
randomly assigned 341 such patients to receive either the
angioplasty and usual medical care, or to forego the angio-
plasty and instead begin immediately on atorvastatin
(80 mg/dl). After eighteen months, 21% of those receiving
standard care had had a major vascular event compared
to only 13% of those with more aggressive LDL-C reduc-
tion. This represents a difference of 36% in the incidence
of recurrent events. The time to the first ischemic event
after randomization was significantly longer in those given
atorvastatin but no angioplasty. At the close of the trial, the
mean LDL-C was 77 mg/dl in the atorvastatin treated
group compared to 119 mg/dl with usual care. It is of note
that over 70% of the latter group had received various
lipid-lowering medications during the trial but at low
doses, and that these were often started later in the study.
Patients who have undergone coronary artery bypass
surgery are at high risk of worsening disease in native
arteries as well as new lesions in the vein grafts. The Post-
Coronary Artery Bypass Graft study (Post-CABG) [20]
selected 1351 patients who had undergone this proce-
dure one to eleven years earlier, had LDL-C levels of 130
to 175 mg/dl, and who had patent vein grafts. The cohort
was randomly divided into two groups, one to be aggres-
sively treated, and the other to have more modest LDL-C
reduction. Diet and drug regimens containing lovastatin
and cholestyramine were used to titrate the LDL-C to
values of 95 to 97 mg/dl in an aggessively treated group.
These were compared to a second randomly selected
group in which the LDL-C was reduced to only 135 to
137 mg/dl, thus leaving them some 40 mg/dl higher for
the duration of the study. The major question was the rela-
tive protection of the vein grafts. After 4.3 years, the mean
luminal diameter, the number of new lesions, and the per-
centage narrowing at major stenoses were all significantly
better in the group with the greater reduction of LDL-C.
Furthermore, the incidence of new revascularization pro-
cedures was reduced by 29%. The number of major clini-
cal events was also reduced in the aggressively treated
group after an additional three years of monitoring [21].
Large long-term clinical trials using statins have achieved
reductions in LDL-C of 26 to 35% with concomitant reduc-
tions in major vascular disease events of 24 to 37% [9–13].
When considered separately, the cohorts with known CHD
and those without demonstrated a strong trend to lower
event rates with lower group mean LDL-C during treatment
with either drug (simvastatin) or placebo. In the 4S study,
this high-risk group of coronary patients experienced a step-
wise lower incidence of clinical events when ranked by ter-
tiles of LDL-C while on treatment [22]. The lowest tertile on
simvastatin, with LDL-C of less than 104 mg/dl, had an inci-
dence of MI and CAD of 10.8% compared to rates of
13.3% in the middle (LDL-C 105 to 126 mg/dl) and 18.9%
for the upper tertile (>126 mg/dl). Other studies, particularly
those using pravastatin such as Cholesterol And Recurrent
Events (CARE) and West of Scotland Coronary Prevention
Study (WOSCOPS), have not reported similar findings.
Those groups on treatment, who demonstrated a fall in LDL-
C of more than approximately 25%, did not appear to enjoy
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however, that comparisons of subgroups within study
cohorts are often distorted by various biases that are gener-
ated by the assumptions and selection criteria of the study
and by the study procedures themselves. The only scientifi-
cally valid method to measure the benefits of further reduc-
tion in LDL-C is to perform a randomized and blinded
comparison of groups treated to various LDL-C values. For-
tunately, such studies are underway with interesting names
such as Treating to New Targets (TNT), Incremental
Decrease in Endpoints through Aggressive Lipid lowering
trial (IDEAL), Study of the Effectiveness of Additional
Reductions in Cholesterol and Homocysteine (SEARCH),
and Heart Protection. A definitive answer to whether leaving
LDL-C just above 100 mg/dl is adequate or whether a sig-
nificant further risk reduction can be achieved by lowering
LDL-C by an additional 30 to 50%, will be available within
the next five years. However, it should be recognized that
these studies address the middle aged and older individuals
who already have clinically evident disease. The extremely
important question of the optimum LDL-C for children,
young adults, and those without clinical disease will remain
with us for some time.
The future
For the next decade it will be necessary to compromise our
efforts in an attempt to use our current resources to give the
greatest gain in controlling the clinical disease. The cost of
screening, monitoring, and current drugs adds unwanted
economic burdens to most societies. It is in this context that
a rational argument can be made for more relaxed goals than
those medically possible today. However, we should not be
satisfied with the status quo since studies, such as Pathobio-
logical Determinants of Atherosclerosis in Youth (PDAY)
[25], demonstrate that after 30 years of age the majority of
adult patients in the USA already have the disease of arte-
riosclerosis and we are only delaying its clinical appearance.
The result is a growth in the number of elderly patients
whose lives are compromised by vascular disease. Gaining
knowledge of the effects of lowering LDL-C to much lower
levels (ie around 50 mg/dl) is extremely important and rele-
vant to practical issues. Setting targets at this level will soon
be feasible for most patients as new and more powerful
statins appear and as new drugs with totally different mecha-
nisms of action (eg reducing bile acid absorption, cholesterol
absorption and or lipoprotein synthesis) are developed.
Clearer concepts of the total societal costs, as well as the
potential economic benefits of various preventive measures
and treatments, must evolve so that the best policies can be
developed to take advantage of the demonstrated efficacy of
such drugs. With a world already experiencing approximately
11,000,000 deaths annually from CHD and stroke [1], the
potential volume of usage will put major pressure on those
attempting to reduce costs and improve efficiency of drug
and health care delivery systems. Current trends strongly
indicate that earlier treatment and more aggressive goals for
LDL-C reduction will be targets for the future.
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